

## Product Information

### Anti-Crk-II

produced in rabbit, IgG fraction of antiserum

Catalog Number **C0853**

#### Product Description

Anti-Crk-II is produced in rabbit using as immunogen a synthetic peptide K-THVRLLDQQNPDEDFS corresponding to the C-terminal of human Crk-II (amino acids 289-304 with N-terminally added lysine), conjugated to KLH. This sequence is identical to the corresponding mouse and chicken Crk-II sequences, and highly conserved (single amino acid substitution) in rat Crk-II. This sequence is absent in Crk-I isoform and has limited homology (60%) to Crk-L. Whole antiserum is purified to provide an IgG fraction of antiserum

Anti-Crk-II recognizes human and chicken Crk-II (38 kDa). Applications include the detection and localization of Crk-II by immunoblotting. Staining of Crk-II in immunoblotting is specifically inhibited with Crk-II immunizing peptide.

Crk proteins are members of a family of adaptor proteins involved in signal transduction, including Grb2 and Nck, which consist mostly of Src homology 2 and 3 (SH2 and SH3) domains. Crk was originally isolated as a transforming component of the avian sarcoma virus CT10 encoding the oncogene product v-Crk.<sup>1,2,3</sup> The cellular homologs of v-Crk, include Crk-I, Crk-II and CrkL. Crk-I and Crk-II are produced by the same *crk* gene by alternative splicing.<sup>4</sup> The major Crk transforming activity appears to be associated with Crk-I. The Crk-II protein (also termed p38, 40/42 kDa, calculated MW 34 kDa), has an N-terminal SH2 domain and two SH3 domains. The Crk-I protein (28 kDa) lacks the C-terminal SH3 domain. The CrkL protein (39 kDa) is similar to Crk-II (60% homology), but is encoded by a different gene. The Crk proteins function as adaptor molecules in several tyrosine kinase signal transduction pathways.<sup>5</sup> The SH2 domain of Crk interacts with tyrosine phosphorylated proteins, such as EGF receptor, p130<sup>Cas</sup> and Cbl, Shc and paxillin, in response to a number of cellular stimuli such as growth factor stimulation, T-cell receptor activation and integrin-mediated cell adhesion.<sup>4,8</sup> Cellular targets for the SH3 domain of Crk include Sos, C3G, c-Abl, DOCK180 and EPS15.<sup>4,9-11</sup> Sos and C3G proteins are efficiently recruited by Crk to the p130<sup>Cas</sup>-Crk signaling complex

upon cellular activation. Both the SH2 and SH3 domains of the human Crk protein are required for neuronal differentiation of PC12 cells, suggesting that Crk plays a role in NGF-signaling involving activation of the p21<sup>ras</sup> signaling pathway.<sup>12</sup>

#### Reagents

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

#### Storage/Stability

Store at -20 °C. For continuous use, the product may be stored at 2-8 °C for up to one month. For extended storage, freeze in working aliquots at -20 °C. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

#### Product Profile

**Immunoblotting:** a minimum working dilution of 1:5,000 is determined using a whole extract of chicken fibroblasts.

**Immunoblotting:** a minimum working dilution of 1:3,000 is determined using a whole extract of the Burkitt lymphoma Raji cell line.

**Note:** In order to obtain the best results and assay sensitivity in various techniques and preparations, we recommend determining optimal working dilutions by titration.

#### References

1. Reichman, C.T., *Cell Growth Differ.*, **3**, 451 (1992).
2. Matsuda, M., et al., *Mol. Cell. Biol.*, **11**, 1607 (1990).

3. Matsuda, M., et al., *Mol. Cell. Biol.* **12**, 3482 (1992).
4. Matsuda, M., Kurata, T., *Cell Signal.*, **5**, 335 (1996).
5. Birge, R.B., et al., *J. Biol. Chem.*, **267**, 10588 (1992).
6. Nojima, Y., et al., *J. Biol. Chem.*, **270**, 15398 (1995).
7. Ribon, V., et al., *Mol. Cell. Biol.*, **16** 45 (1996).
- 8.
9. Reedquist, K.A., et al., *J. Biol. Chem.*, **271**, 8435 (1996).
10. Matsuda, M., et al., *Mol. Cell. Biol.*, **14**, 5495 (1994).
11. Tanaka, S., et al., *Proc. Natl. Acad. Sci. USA*, **91** 3443 (1994).
12. Matsuda, M., et al., *J. Biol. Chem.*, **271**, 14468 (1996).
13. Tanaka, S., et al., *Mol. Cell. Biol.*, **7**, 4409 (1993).

MG,KAA,PHC 07/10-1